THE LANCET
Gastroenterology & Hepatology

## Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Solomon S S, Wagner-Cardoso S, Smeaton L, et al. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. *Lancet Gastroenterol Hepatol* 2022; published online Jan 10. https://doi.org/10.1016/S2468-1253(21)00397-6.

# SUPPLEMENTARY MATERIALS

**Table of Contents**

**Study Sites and Teams**

Amy K. Sbrolla and Connor Reynolds from Massachusetts General Hospital (CRS: 101; CRS Grant: UM1AI069412). Paul Sax and Cheryl Keenan from Brigham and Women's Hospital (CRS: 107; CRS Grant: UM1AI069412). Ilene Wiggins and Juhi Moon from Johns Hopkins University (CRS: 201; CRS Grant: UM1AI069465). Debika Bhattacharya and Samantha Fortier from UCLA CARE Center (CRS: 601; CRS Grant: 2UM1AI069424). Steven Hendrickx and Mark Fernandez from UCSD Antiviral Research Center (CRS: 701; CRS Grant: UM1AI069432). Jay Dwyer and Daniel Berrner from UCSF AIDS (CRS: 801; CRS Grant: UCLA MCA 20190973). Jen Sullivano and Amanda Saylor from University of Pittsburgh (CRS: 1001; CRS Grant: U01AI06949402). Noah Wald-Dickler and Connie Funk from University of Southern California (CRS: 1201; CRS Grant: 5UM1AI069432). Teresa Spitz and Michael Royal from Washington University (CRS: 2101; CRS Grant: UM1AI069439). Carlos Malvestutto and Mark Hite from Ohio State University Medical Center (CRS: 2301; CRS Grant: UM1AI069494). Carl J. Fichtenbaum and Michelle Saemann from Cincinnati (CRS: 2401; CRS Grant: UM1AI069501). Donald Anthony and Carla Hernandez from Case Western (CRS: 2501; CRS Grant: AI069501). Claudia Hawkins and Sherrie Wolfe from Northwestern University CRS (CRS: 2701; CRS Grant: 5UM1 AI069471). Beverly E. Sha and Rebecca Lai from Rush University Medical Center (CRS: 2702; CRS Grant: U01 AI069471). Pamela Poethke and Karen Tashima from The Miriam Hospital (CRS: 2951; CRS Grant: AI069412). Jonathan Oakes and Nazneen Howerton from UNC Chapel Hill (CRS: 3201; CRS Grants: 5UM1AI068636, 2UM1AI069423, and UL1TR002489). Cornelius N. Van Dam and Kimberley Epperson from Greensboro (CRS: 3203; CRS Grant: 2UM1AI069423). Frederick Nicotera and Tracey Watkins from Vanderbilt (CRS: 3652; CRS Grants: AI069439 and TR002243). Jorge L. Santana and Sigrid Perez-Fronteras from Puerto Rico AIDS Clinical Trials Unit (PR-AIDS) (CRS: 5401; CRS Grant: 5UM1AI069415). Lesley Miller and Ericka R. Patrick from Emory-CDC Ponce Clinical Research Site (CRS: 5802; CRS Grants: UM1AI69418 and P30A1050409). Andrew Lauria and Suzanne Fiorillo from University of Colorado Hospital (CRS: 6101; CRS Grants: UM1 AI 69432 and UL1 TR002535). Eileen Donaghy and Yan Jiang from Penn Therapeutics (CRS: 6201; CRS Grant: UM1 AI069534). Rebecca Fry and Jiamin Li from Weill Cornell Uptown (CRS: 7803; CRS Grants: 5UM1AI069419 and UL1TR000457). Valery Hughes and Shaun Barcavage from Weill Cornell Chelsea (CRS: 7804; CRS Grants: 5UM1AI069419 and UL1TR000457). Lynne Cornelissen and Lindee Ganger from Family Centre for Research with Ubuntu, Stellenbosch University, Cape Town, South Africa (CRS: 8950; CRS Grants: 2UM1AI068636 and

Gilead/MGH UM1AI068636). Jaclyn Bennet and Sharlaa Badal-Faesen from Wits Helen Joseph (CRS: 11101; CRS Grants: AI069463 and AI068636). Alessandro Nascimento and Hugo Perazzo from the Instituto de Pesquisa Clínica Evandro Chagas (IPEC) (CRS: 12101; CRS Grant: UM1AI069476). Rita de Cassia Aleves Lira and Andre Luis Machado da Silva from Hospital Nossa Senhora da Conceição, Brazil (CRS: 12201; CRS Grant: AI069424). Samuel Kawuma and Francis Ssali from JCRC Kampala CRS (CRS: 12401; CRS Grant: UM1AI069501). Jolene Noel-Connor and Matthew Scherer from Columbia P&S (CRS: 30329; CRS Grant: UM1AI069470). Roger J. Bedimo and Jennifer Klein from Trinity Health & Wellness (CRS: 31443; CRS Grant: UM1AI069471). Roberto C. Arduino and Martine M. Diez from HART (CRS: 31473; CRS Grants: UM1AI069432 and UM1AI068636). Sarah Henn and David Klein from Whitman-Walker Institute (CRS: 31781; CRS Grant: UM1AI069465). Patcharaphan Sugandhavesa and Daralak Tavornprasit from CMU HIV Treatment (CRS: 31784; CRS Grant: UM1AI068636). Debra Chew and Valerie Cadorett from Rutgers New Jersey Medical School (CRS: 31786; CRS Grant: AI69419). Peter Mariuz and Catherine A. Bunce from University of Rochester Adult HIV Therapeutic Strategies (CRS: 31787; CRS Grant: UM1AI069511). Edgar Turner Overton and Olivia Hogue from Alabama CRS (CRS: 31788; CRS Grant: UM1AI069452). Kiat Ruxrungtham and Sivaporn Gatechompol from Thai Red Cross AIDS Research Centre (TRC-ARC) (CRS: 31802; CRS Grant: UM1AI069399).

**Supplementary Figure 1. Study sites participating in the ACTG A5360 MINMON trial.**

**Supplementary Table 1. Recruitment by Study Site**

| Site Name | Number of participants recruited |
|---|---|
| Hospital Nossa Senhora da Conceicao, Brazil | 68 |
| Instituo de Pesquisa Clinica Evandro Chagas, Brazil | 63 |
| Thai Red Cross AIDS Research Centre (TRC-ARC), Thailand | 61 |
| Chiang Mai University HIV Treatment (CMU HIV Treatment), Thailand | 49 |
| Joint Clinical Research Center (JCRC) Kampala, Uganda | 15 |
| University of the Witwatersrand Helen Joseph (WITS HJH) CRS, South Africa | 8 |
| Penn Therapeutics, USA | 8 |
| Puerto Rico AIDS Clinical Trials Unit, USA | 7 |
| Johns Hopkins University, USA | 5 |
| University of California, San Diego AntiViral Research Center, USA | 5 |
| Family Clinical Research Unit (FAM-CRU), South Africa | 4 |
| University of Alabama, USA | 4 |
| Brigham and Women's Hospital Therapeutics (BWHT), USA | 4 |
| Case Western Reserve University, USA | 4 |
| University of North Carolina, Chapel Hill, USA | 4 |
| University of Cincinnati, USA | 4 |
| Columbia Physicians and Surgeons (P and S), USA | 4 |
| Greensboro, USA | 4 |
| Houston AIDS Research Team (HART), USA | 4 |
| Massachusetts General Hospital (MGH), USA | 4 |
| New Jersey Medical School Clinical Research Center, USA | 4 |
| Northwestern University, USA | 4 |
| Ohio State University, USA | 4 |
| Rush University, USA | 4 |
| The Miriam Hospital (TMH), USA | 4 |
| Trinity Health and Wellness Center, USA | 4 |
| University of California, Los Angeles CARE Center, USA | 4 |
| University of California, San Francisco HIV/AIDS, USA | 4 |
| University of Colorado Hospital, USA | 4 |
| University of Pittsburgh, USA | 4 |
| University of Rochester Adult HIV Therapeutic Strategies Network, USA | 4 |
| University of Southern California, USA | 4 |
| Vanderbilt Therapeutics (VT), USA | 4 |
| Washington University Therapeutics (WT), USA | 4 |
| Weill Cornell Chelsea, USA | 4 |
| Weill Cornell Uptown, USA | 4 |
| Whitman Walker Health, USA | 4 |
| The Ponce de Leon Center, USA | 3 |

**Supplementary Table 2. Unplanned Study Visits**

| Country | Age in years | Sex at birth | Days since SOF/VEL initiation | Reason for visit | Visit related to a reportable Adverse Event | Visit resulted in SOF/VEL discontinuation | Sustained Virologic Response |
|---|---|---|---|---|---|---|---|
| South Africa | 67 | Male | 1 | Grade 4 sodium abnormality detected at entry | No | No | Yes |
| | | | 4 | Repeat sodium | No | No | |
| | | | 11 | Repeat sodium | No | No | |
| Thailand | 27 | Male | 5 | Follow-up of liver function test | No | No | Yes |
| USA | 53 | Male | 5 | Symptoms of upper respiratory infection | Yes | No | Yes |
| Uganda | 51 | Male | 7 | Participant felt unwell | No | No | Yes |
| Uganda | 49 | Male | 13 | Participant complained of frequent micturition | No | No | Yes |
| Uganda | 31 | Male | 22 | Participant complained of headache and dizziness | No | No | Yes |
| Brazil | 63 | Female | 34 | Community acquired pneumonia | No | No | Yes |
| | | | 46 | Clarification about treatment | No | No | |
| Brazil | 35 | Male | 40 | Papular rash | No | No | Yes |
| | | | 43 | Rash on face and thorax | No | No | |
| Thailand | 42 | Male | 43 | Repeat AST/ALT from previous visit | No | No | Yes |
| South Africa | 51 | Female | 48 | Participant complained of weakness | Yes | No | Yes |
| | | | 49 | Participant requested to visit site to repeat hemogram | No | No | |
| | | | 50 | Participant came to site for counseling and administration of vitamin B12 for management of pernicious anemia | No | No | |
| Thailand | 30 | Male | 48 | Repeat AST/ALT | No | No | Yes |
| USA | 59 | Male | 72 | Blood evaluations to evaluate dizziness and other symptoms | No | No | Yes |
| Thailand | 34 | Male | 85 | Participant diagnosed with HIV and wanted to start antiretroviral therapy | No | No | Yes |
| Brazil | 63 | Female | 96 | Grade 2 rash | Yes | No | Yes |
| USA | 59 | Female | 151 | Participant came in early for study visit | No | No | No |

**Supplementary Table 3. Serious Adverse Events Reported Between Entry and Week 28**

| Country | Days since SOF/VEL initiation | Description of SAE | Toxicity Grade | Related to SOF/VEL | Resulted in SOF/VEL discontinuation | SAE outcome |
|---|---|---|---|---|---|---|
| USA | 20 | Respiratory Failure | 3 | No | No | Recovered |
| South Africa | 48 | Anemia | 4 | No | No | Recovered |
| Thailand | 53 | Drug overdose | 3 | No | No | Recovered |
| Thailand | 65 | Dyspepsia | 3 | No | No | Recovered |
| Thailand | 67 | Pneumonia | 3 | No | No | Recovered |
| USA | 89 | Depression | 3 | No | Not applicable* | Resolving |
| Thailand | 101 | Acute myocardial infarction | 4 | No | Not applicable* | Recovered |
| USA | 127 | Acute right ventricular failure | 3 | No | Not applicable* | Recovered |
| Thailand | 131 | Diverticular perforation | 3 | No | Not applicable* | Recovered |
| USA | 148 | Hypertension | 3 | No | Not applicable* | Recovered |
| South Africa | 157 | Seizure | 3 | No | Not applicable* | Recovered |
| USA | 168 | Acute kidney injury | 3 | No | Not applicable* | Recovered |
| USA | 178 | Urinary tract infection | 3 | No | Not applicable* | Recovered |
| USA | 193 | Suicidal ideation | 3 | No | Not applicable* | Recovered |

*Not applicable as study medication was completed